By Grace Yoon
Shares of Clarivate fell after the company said it was selling its life-science and healthcare segment to Altaris, a New York investment firm, for $600 million.
The stock was down 4.8% to $2.47 in recent trading, and has fallen over 26% since the start of the year.
Clarivate, a London-based provider of global information, analytics and workflow solutions, said the sale would allow it to focus on AI-driven intelligence for its academic and government and intellectual-property segments.
Clarivate said it expects to complete the sale by the end of the year.
Write to Grace Yoon at grace.yoon@wsj.com